This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Seattle Genetics, Inc.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Thomas Manley - Innovator in Antibody Drug Conjugate Therapy
Introduction
Thomas Manley is a notable inventor based in Bothell, WA (US). He has made significant contributions to the field of medicine, particularly in the development of therapies that aim to reduce side effects associated with cancer treatments. His work is particularly focused on improving the quality of life for patients undergoing antibody drug conjugate therapy.
Latest Patents
Thomas Manley holds a patent for "Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy." This patent outlines methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, which may also include accompanying chemotherapy. The adverse events addressed in this patent include peripheral neuropathy and neutropenia, which are common side effects of such treatments.
Career Highlights
Manley is currently employed at Seattle Genetics, Inc., a company renowned for its innovative approaches to cancer treatment. His work at Seattle Genetics has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research that has the potential to change the landscape of cancer therapy.
Collaborations
One of his notable coworkers is Neil Josephson, with whom he has likely collaborated on various projects aimed at enhancing patient outcomes in cancer treatment.
Conclusion
Thomas Manley's contributions to the field of antibody drug conjugate therapy exemplify the impact of innovative thinking in medicine. His patent and work at Seattle Genetics, Inc. highlight his commitment to improving patient care and reducing the side effects of cancer treatments.